Common Contracts
13 similar Underwriting Agreement contracts by Adma Biologics, Inc., Alerus Financial Corp, Amedisys Inc, others
UNDERWRITING AGREEMENTUnderwriting Agreement • December 7th, 2022 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 20,979,020 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 20,979,020 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 3,146,853 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
•] Shares* BOUNTY MINERALS, INC. Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 1st, 2022 • Bounty Minerals, Inc. • Crude petroleum & natural gas • New York
Bounty Minerals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [•] shares of its Class A common stock, $0.01 par value per share (the “Class A Common Stock”). Such aggregate of [•] shares to be purchased from the Company by the Underwriters are called the “Firm Shares.” In addition, the Company has agreed to issue and sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [•] shares of Class A Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this agreement (this “Agreement”) as the “Shares.” As part of the offering contemplated by this Agreement, the Representative (as defined below) has agreed to reserve out of the Firm Shares purchased by it under this Agreement u
50,000,000 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 21st, 2021 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 50,000,000 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 50,000,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 7,500,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
UNDERWRITING AGREEMENT United States Steel Corporation 42,000,000 Shares of Common Stock, Par Value $1.00 Per ShareUnderwriting Agreement • February 5th, 2021 • United States Steel Corp • Steel works, blast furnaces & rolling mills (coke ovens) • New York
United States Steel Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the Underwriter listed in Schedule 1 hereto (the “Underwriter”) an aggregate of 42,000,000 shares of common stock, par value $1.00 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriter, up to an additional 6,300,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Common Stock.”
14,285,714 Shares1 LIPOCINE INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2021 • Lipocine Inc. • Pharmaceutical preparations • New York
Lipocine Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 14,285,714 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 14,285,714 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 2,142,857 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
Shares* AVADIM HEALTH, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 17th, 2020 • Avadim Health, Inc. • Perfumes, cosmetics & other toilet preparations • New York
Avadim Health, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. and SunTrust Robinson Humphrey, Inc. are acting as the representatives of the several Underwriters and in such capacity are referred to in this agreement (the “Agreement”) as the “Representatives.”
] Shares(1) ALERUS FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 16th, 2019 • Alerus Financial Corp • National commercial banks • New York
Alerus Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [ ] shares of the Company’s Common Stock, par value $1.00 per share (the “Common Stock”). The aggregate of [ ] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [ ] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this agreement (this “Agreement”) as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as “you” or the “Representative.”
] Shares(1) ALERUS FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2019 • Alerus Financial Corp • National commercial banks • New York
Alerus Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [ ] shares of the Company’s Common Stock, par value $1.00 per share (the “Common Stock”). The aggregate of [ ] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [ ] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this agreement (this “Agreement”) as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as “you” or the “Representative.”
2,400,000 Shares* HOWARD BANCORP, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 1st, 2017 • Howard Bancorp Inc • State commercial banks • Florida
Howard Bancorp, Inc., a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,400,000 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 2,400,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 360,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
T-MOBILE US, INC. 66,150,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • November 20th, 2013 • T-Mobile US, Inc. • Radiotelephone communications • New York
T-Mobile US, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 66,150,000 shares of Common Stock, par value $0.00001 per share, of the Company (the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 6,615,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
MCMORAN EXPLORATION CO. 75,000 Shares Underwriting Agreement June 16, 2009Underwriting Agreement • June 19th, 2009 • McMoran Exploration Co /De/ • Crude petroleum & natural gas • New York
McMoRan Exploration Co., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 75,000 shares of 8.0% Convertible Perpetual Preferred Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 11,250 shares of 8.0% Convertible Perpetual Preferred Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”.
SEATTLE GENETICS, INC. 5,740,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 28th, 2009 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
Seattle Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the one or more several Underwriters listed in Schedule 1 hereto (whether one or more, the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 5,740,000 shares of common stock, par value $0.001 per share, of the Company (the “Shares”). The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.
3,000,000 Shares* Amedisys, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 3rd, 2006 • Amedisys Inc • Services-home health care services • New York
Amedisys, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 3,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The aggregate of 3,000,000 shares of Common Stock to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 450,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
